Discontinuation of tyrosine kinase inhibitors based on BCR-ABL1 monitoring by digital droplet PCR in pediatric chronic myeloid leukemia

Lifelong treatment of pediatric chronic myeloid leukemia (CML) patients with tyrosine kinase inhibitors (TKIs) can affect their growth and development. For these reasons, clinical trials have explored the feasibility of TKI discontinuation in children with a sufficient TKI response. We evaluated the...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Yeojae, Kim, Seongkoo, Lee, Jong Mi, Ahn, Ari, Yoo, Jae Won, Lee, Jae Wook, Cho, Bin, Chung, Nack-Gyun, Kim, Yonggoo, Kim, Myungshin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363655/
https://www.ncbi.nlm.nih.gov/pubmed/35967571
http://dx.doi.org/10.3389/fped.2022.928136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363655/
https://www.ncbi.nlm.nih.gov/pubmed/35967571
http://dx.doi.org/10.3389/fped.2022.928136

Ejemplares similares